inPractice® - Lamivudine

Lamivudine is appropriate for use in persons coinfected with HIV and HBV if administered in combination with other agents with anti-HBV activity in the context of an antiretroviral therapy regimen and at the dose used in the treatment of HIV (300 mg daily) (Management Guidelines)^{[DHHS ART]}
Incidence of lamivudine-resistant HBV is approximately 20% per year in people with HIV if taken as monotherapy for HBV and reaches 90% at 4 years^{[Dore 1999; Benhamou 1999; Pillay 2000]}